Parametrica Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Parametrica Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,300	Closed	-$1.37M	–	94
2024 Q3	$1.37M	Buy	+1,300	New	+$1.45M	1.63%	17
2024 Q2	–	Sell	-1,600	Closed	-$1.54M	–	29
2024 Q1	$1.54M	Sell	1,600 -13	-0.8%	-$12.4K	2.22%	14
2023 Q4	$1.42M	Sell	1,613 -2,330	-59%	-$1.92M	2.33%	14
2023 Q3	$3.24M	Sell	3,943 -41	-1%	-$32.2K	5.46%	6
2023 Q2	$2.86M	Buy	3,984 +861	+28%	+$664K	5.51%	6
2023 Q1	$2.57M	Buy	+3,123	New	+$2.36M	4.63%	8
2021 Q1	–	Sell	-1,773	Closed	-$857K	–	220
2020 Q4	$857K	Buy	+1,773	New	+$957K	0.53%	40
2016 Q2	–	Sell	-1,120	Closed	-$404K	–	231
2016 Q1	$404K	Buy	+1,120	New	+$462K	1.45%	13

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parametrica Management's REGN Position: Q4 2024 in Review

Parametrica Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 1,300 shares — an estimated $1.37M sold.

Parametrica Management first reported a position in REGN in Q1 2016 and held it in 8 quarters. The position peaked at $3.24M in Q3 2023. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Parametrica Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Parametrica Management sold 1,300 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $1.37M.
Parametrica Management first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Parametrica Management's Regeneron Pharmaceuticals position peaked at $3.24M in Q3 2023.
1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Parametrica Management's 13F filing for Q4 2024, filed 12 Feb 2025.